PeptidePrices safety rating
8/10 · FDA-approved (Victoza/Saxenda)
Liraglutide Prices
1 vendor · 0 with an issuer-verified COA · lowest 10mg from $60.21 · checked
Where to buy Liraglutide: 1 vendor compared
| Vendor | Price | Actions |
|---|---|---|
| $60.2110mg packageChecked today | Buy Liraglutide from Kensington Labs |
Tracked every day
Liraglutide listing prices, tracked daily
The five cheapest in-stock package prices for Liraglutide on each collected day, and the vendors that most often held those places.
Five cheapest in-stock package prices per day
Listed package price before coupons, any vial size. This is not the coupon-adjusted lowest 10mg price used to rank the comparison.
- Cheapest$53.51
- 2nd cheapest$60.21
Vendors most often in the cheapest five
- Kensington Labs34 days$60.21-9.9%
Current market data
Liraglutide Price Report
A current summary of public listings after the price comparison above. Shipping and tax are not included.
The lowest current 10mg cost for Liraglutide is $60.21 from Kensington Labs. The median across vendors is $60.21.
- Lowest 10mg cost
- $60.21Kensington Labs
- Median 10mg cost
- $60.21One normalized offer per vendor
- Lowest package total
- $53.51Kensington Labs · package size may differ
- Public COA coverage
- 100%1 of 1 vendors
What the market shows
PeptidePrices found 2 in-stock listings from 1 vendor, checked through Oct 9, 2026. The lowest 10mg cost is 0% below the vendor median of $60.21; 0 vendors (0%) fall below that median. 1 of 1 vendors (100%) publish public COA evidence.
A public COA link shows that a vendor publishes testing data. It does not prove that every listed vial has a matching current report. Match the product, strength, batch, and lot before relying on a report.
How this report is calculated
The headline and median use each vendor's lowest whole-package checkout cost to obtain at least 10mg. Smaller packages are multiplied until the target is met, while larger packages retain their full checkout price. The lowest package total is shown only as secondary context because package sizes differ. Known public coupon discounts are applied. Shipping, tax, and unverified promotions are excluded.
Research context
What is Liraglutide? Research, safety, and status
Liraglutide at a glance
Mechanism
GLP-1 receptor agonist (97% homology to human GLP-1); stimulates insulin secretion, inhibits glucagon, slows gastric emptying, reduces appetite. Daily injection (vs. weekly for GLP-1S).
Research areas
Type 2 diabetes management; weight loss (Saxenda); cardiovascular risk reduction; appetite suppression.
Regulatory / research status
FDA approved (for specific indications)
Half-life
~13 hours. Daily SC injection required.
Storage
Lyophilized vial: store at -20°C long-term or 2-8°C short-term, protected from light.
Reported side effects
Nausea, vomiting, diarrhea, constipation; pancreatitis risk; thyroid C-cell tumor risk (rodents); gallbladder disease.
Extensive data; GI side effects; thyroid warning (animal); cardiovascular benefit demonstrated Safety ratings summarize published clinical data, adverse-event reporting, and regulatory status. How PeptidePrices rates evidence. Research information only, not medical advice.
Study highlights
- The SCALE Obesity trial (NEJM 2015, n=3,731) demonstrated that liraglutide 3.0 mg as Saxenda produced a mean 8.4% body weight reduction vs 2.8% with placebo over 56 weeks, with 63.2% of participants achieving ≥5% weight loss, leading to FDA approval for chronic weight management.
- The LEADER cardiovascular outcomes trial (NEJM 2016, n=9,340) showed liraglutide 1.8 mg significantly reduced the MACE composite endpoint by 13% (HR 0.87, p=0.01) in T2D patients at high cardiovascular risk over a median 3.8 years, establishing the first cardiovascular mortality benefit for a GLP-1 agonist.
- Liraglutide activates GLP-1 receptors with 97% amino acid homology to native GLP-1, with a C-16 fatty acid attachment enabling albumin binding and a half-life of ~13 hours allowing once-daily dosing; effects include glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and hypothalamic appetite suppression.
- FDA approved liraglutide (Victoza) for T2D in 2010 and Saxenda 3.0 mg for chronic weight management in adults in 2014, with a pediatric weight management expansion in 2020 for patients aged 12 and older, making it the first GLP-1 agonist approved for pediatric obesity.
Selected references
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity) · New England Journal of Medicine, 2015
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER) · New England Journal of Medicine, 2016
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes RCT · JAMA, 2015
- Saxenda (Liraglutide 3 mg) Prescribing Information · FDA, 2023
- FDA Approves Weight Management Drug for Patients Aged 12 and Older · FDA, 2020
- Weight Maintenance and Additional Weight Loss with Liraglutide After Low-Calorie-Diet-Induced Weight Loss (SCALE Maintenance) · PubMed, 2013
Related pages